← Leaderboards
Song Li
University Of Pittsburgh At Pittsburgh
$19,394,480
Attributed
$22,239,232
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,239,232 · 17
By mechanism
R01$20,070,787 · 13
R21$1,169,165 · 3
U19$999,280 · 1
Top collaborators
- Binfeng Lu6 shared
- Ajay Nmn Rana5 shared
- Yong Tae Kwon3 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Hulya Bayir$16,376,338
- Pei Tang$11,876,344
- Robert S. Clark$12,893,742
- Peter X Wipf$9,740,940
- Rob D Coalson$815,671
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseIn VivoTumorToxic EffectPharmaceutical PreparationsTreatment EfficacyMalignant NeoplasmsTherapeutic EffectLeadMediatingNeoplastic CellMouse ModelProteinsOverexpressionPaclitaxelPathway InteractionsCellsTumor TissuePlasmidsNanoparticleCancer CellCancer TypeMalignant Breast NeoplasmBiological Availability
Grant awards (65)
Targeting iRhom to Improve Colon Cancer Immunochemotherapy$546,625
R01 · FY2025 · CA · contact PI
Nanoparticles-mediated combination therapy for breast cancer$501,746
R01 · FY2025 · CA · contact PI
Combination Therapy for Pancreatic Cancer$472,623
R01 · FY2025 · CA · contact PI
Nanoparticles-mediated combination therapy for breast cancer$476,617
R01 · FY2024 · CA · contact PI
Combination Therapy for Pancreatic Cancer$448,992
R01 · FY2024 · CA · contact PI
Nanoparticles-mediated combination therapy for breast cancer$516,189
R01 · FY2023 · CA · contact PI
Combination Therapy for Pancreatic Cancer$472,623
R01 · FY2023 · CA · contact PI
Study of Interleukin 33 as a new immunotherapy of lung cancer$433,485
R01 · FY2023 · CA
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer$349,821
R01 · FY2022 · CA · contact PI
Study of Interleukin 33 as a new immunotherapy of lung cancer$266,925
R01 · FY2022 · CA
Study of Interleukin 33 as a new immunotherapy of lung cancer$81,376
R01 · FY2022 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy$454,633
R01 · FY2021 · CA · contact PI
Developing Nano Technology for HER2 Directed Therapy$428,652
R01 · FY2021 · CA
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer$356,960
R01 · FY2021 · CA · contact PI
Study of Interleukin 33 as a new immunotherapy of lung cancer$355,409
R01 · FY2021 · CA
Developing Nano Technology for HER2 Directed Therapy$680,572
R01 · FY2020 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy$454,633
R01 · FY2020 · CA · contact PI
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer$356,960
R01 · FY2020 · CA · contact PI
Study of Interleukin 33 as a new immunotherapy of lung cancer$355,409
R01 · FY2020 · CA
Developing Nano Technology for HER2 Directed Therapy$678,715
R01 · FY2019 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy$440,990
R01 · FY2019 · CA · contact PI
Study of Interleukin 33 as a new immunotherapy of lung cancer$355,409
R01 · FY2019 · CA
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer$345,749
R01 · FY2019 · CA · contact PI
Developing Nano Technology for HER2 Directed Therapy$463,483
R01 · FY2018 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy$454,390
R01 · FY2018 · CA · contact PI
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer$354,559
R01 · FY2018 · CA · contact PI
Targeted Combination Therapy for Breast Cancer$313,136
R01 · FY2018 · CA · contact PI
Developing Nano Technology for HER2 Directed Therapy$505,138
R01 · FY2017 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy$451,366
R01 · FY2017 · CA · contact PI
Targeted Combination Therapy for Breast Cancer$313,323
R01 · FY2017 · CA · contact PI
Targeted Combination Therapy for Breast Cancer$313,504
R01 · FY2016 · CA · contact PI
Rational Design of Lipidic Vectors for Mitochondria-Targeted Antioxidants$286,898
R01 · FY2016 · GM · contact PI
Role of Ubiquitin in Cardiovascular System$366,157
R01 · FY2015 · HL · contact PI
Targeted Combination Therapy for Breast Cancer$313,680
R01 · FY2015 · CA · contact PI
Rational Design of Lipidic Vectors for Mitochondria-Targeted Antioxidants$287,064
R01 · FY2015 · GM · contact PI
Role of Ubiquitin in Cardiovascular System$364,500
R01 · FY2014 · HL · contact PI
Targeted Combination Therapy for Breast Cancer$312,128
R01 · FY2014 · CA · contact PI
Rational Design of Lipidic Vectors for Mitochondria-Targeted Antioxidants$286,775
R01 · FY2014 · GM · contact PI
Smart Drug Delivery$168,179
U19 · FY2014 · AI · contact PI
Nanomicellar Formulation for Synergistic Targeting of Prostate Cancer$162,188
R21 · FY2014 · CA · contact PI
Role of Ubiquitin in Cardiovascular System$354,274
R01 · FY2013 · HL · contact PI
Rational Design of Lipidic Vectors for Mitochondria-Targeted Antioxidants$284,677
R01 · FY2013 · GM · contact PI
Nanomicellar Formulation for Synergistic Targeting of Prostate Cancer$199,013
R21 · FY2013 · CA · contact PI
Smart Drug Delivery$160,111
U19 · FY2013 · AI · contact PI
Non Viral Gene Therapy for Lung Injury$374,963
R01 · FY2012 · HL · contact PI
Smart Drug Delivery$207,607
U19 · FY2012 · AI · contact PI
Polymeric System for Synergistic Targeting of AR Signaling in Prostate Cancer$164,756
R21 · FY2012 · CA · contact PI
Non Viral Gene Therapy for Lung Injury$378,750
R01 · FY2011 · HL · contact PI
Smart Drug Delivery$232,074
U19 · FY2011 · AI · contact PI
Polymeric System for Synergistic Targeting of AR Signaling in Prostate Cancer$197,708
R21 · FY2011 · CA · contact PI
Non Viral Gene Therapy for Lung Injury$378,750
R01 · FY2010 · HL · contact PI
Smart Drug Delivery$231,309
U19 · FY2010 · AI · contact PI
Non Viral Gene Therapy for Lung Injury$378,750
R01 · FY2009 · HL · contact PI
Nanosized Delivery System for Site-Specific Drug Release$148,500
R21 · FY2009 · CA · contact PI
Nanosized Delivery System for Site-Specific Drug Release$148,500
R21 · FY2008 · CA · contact PI
Nanosized Delivery System for Site-Specific Drug Release$148,500
R21 · FY2007 · CA · contact PI
Pharmacogenetic Therapy of Pulmonary Hypertension$358,613
R01 · FY2006 · HL · contact PI
Pharmacogenetic Therapy of Pulmonary Hypertension$367,360
R01 · FY2005 · HL
Pharmacogenetic Therapy of Pulmonary Hypertension$367,474
R01 · FY2004 · HL
LIPID-MEDIATED GENE TRANSFER TO PULMONARY ENDOTHELIUM$255,336
R01 · FY2004 · HL
Pharmacogenetic Therapy of Pulmonary Hypertension$331,455
R01 · FY2003 · HL
LIPID-MEDIATED GENE TRANSFER TO PULMONARY ENDOTHELIUM$255,336
R01 · FY2003 · HL
LIPID-MEDIATED GENE TRANSFER TO PULMONARY ENDOTHELIUM$255,539
R01 · FY2002 · HL
LIPID-MEDIATED GENE TRANSFER TO PULMONARY ENDOTHELIUM$256,148
R01 · FY2001 · HL
LIPID-MEDIATED GENE TRANSFER TO PULMONARY ENDOTHELIUM$256,148
R01 · FY2000 · HL